Reduced Expression of TET1, TET2, TET3 and TDG mRNAs Are Associated with Poor Prognosis of Patients with Early Breast Cancer

Liu Yang¹, San-Jian Yu¹*, Qi Hong¹,²*, Yu Yang³, Zhi-Ming Shao¹,²*

¹ Department of Breast Surgery, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, ² Institutes of Biomedical Sciences, Fudan University, Shanghai, P.R. China, ³ School of basic medical sciences, Chengdu University of traditional Chinese medicine, Chengdu, P.R. China

☯ These authors contributed equally to this work.
* zhimingshao@yahoo.com

Abstract

Purpose
The purpose of this study was to determine the prognostic role of ten eleven translocation (TET) family proteins and DNA glycosylase (TDG) in patients with early breast cancer (EBC).

Methods
Expression of mRNAs encoding TET1–3 and TDG in 162 breast cancer tissues was quantified using real-time polymerase chain reaction analysis. The general characteristics of patients and clinicopathologic factors were collected. Estimation of patient survival was calculated using the Kaplan–Meier method, and independent prognostic indicators were analyzed using Cox regression analysis.

Results
The level of TET1 mRNA was significantly related to overall survival (OS) (P = 0.022). Multivariate analysis shows that the TNM stage was an independent predictor of disease-free survival (DFS) (HR = 1.761, 95% CI: 1.124–2.761, P = 0.014) and OS (HR = 2.135, 95% CI: 1.070–4.263, P = 0.032). Further, in patients with EBC who were treated with anthracyclines, Kaplan–Meier analysis indicates that the levels of TET3 and TDG mRNAs were related to DFS (P = 0.026 and 0.030, respectively), and multivariate analysis reveals that high levels of TET3 (HR = 1.944, 95% CI: 1.029–3.672, P = 0.040) and TDG (HR = 2.178, 95% CI: 1.140–4.163, P = 0.018) mRNAs were independent indicators of favorable DFS.
Conclusions

Our study indicates that EBC patients with decreased expression of TET1 mRNA had worse OS and that the levels of TET3 and TDG mRNAs were independent prognostic factors for patients who received anthracycline chemotherapy.

Introduction

Breast cancer is one of the most commonly diagnosed cancers in women, with an estimated 1.2 million new cases worldwide each year, and represents approximately 25% of cancers of women [1, 2]. Patients respond well to treatment, and standard guideline has been promoted in our country in recent years; however, breast cancer remains the second most frequent cause of cancer-related deaths, and 1.2 million people die each year in our country [3, 4]. The development of new techniques to predict the prognosis of breast cancer is crucial for administering more timely and appropriate treatment, and further research is required to identify novel molecular markers of prognosis.

The influence of epigenetics has contributed to the understanding of the complexities of gene regulation, cell differentiation, aging, and disease [5–8], and aberrant epigenetic profiles are associated with the pathogenesis of cancer [9, 10]. For example, methylation of promoter regions leads to epigenetic gene silencing, particularly methylation of cytosine residues in CpG islands [11], which is a short stretch of DNA with higher frequency of the CG sequence than other regions, locating around the promoters of housekeeping genes or other genes frequently expressed in a cell. And further, dysregulated DNA methylation of tumor suppressor genes occurs in different types of cancer [12]. Marc Milstein [13] reported that RIN1 gene was silenced in breast tumor cell lines compared to cultured human mammary epithelial cells and DNA methylation within the RIN1 promoter contributed to silence of the gene.

Conversely, DNA demethylation occurs in different biological contexts, and this alteration can occur passively or actively [14]. Passive DNA demethylation refers to the loss of 5-methylcytosine (5mC) residues by gradual dilution in a replication-dependent manner. The active process involves TET family proteins and TDG. Oxidation of 5mC to 5-hydroxymethylcytosine (5hmC) by TET proteins is the key process of active DNA demethylation. Further oxidation of 5hmC by TET generates 5-formylcytosine (5fC) and 5-carboxylcytosine (5caC), which can be actively removed from the genome by TDG [15, 16].

The TET family of DNA dioxygenases TET1, TET2, and TET3 require α-ketoglutarate and Fe²⁺ for activity [14]. Loss-of-function mutations or decreased expression of TETs and TDG inhibits the DNA demethylation pathway, which prevents the removal of 5mC from genomic DNA. And aberrant methylation of tumor suppressor genes may lead to tumorigenesis. TET2 mutations, such as gene deletion, occur in chronic myelomonocytic leukemia, acute myeloid leukemia, and myelodysplastic syndromes as well as in solid tumors, including clear-cell renal cell carcinoma, prostate cancer, and breast cancer [17–21]. Moreover, mutations of the three TET genes were detected in colorectal cancer [22], and there is a close correlation between TET expression and robust tumor growth and metastasis [23–25]. Yang et al. [26] reported that the levels of 5hmC are dramatically reduced in human breast cancer and that the expression of the three TET genes was significantly reduced in breast cancer, particularly that of TET1. They further found that 5hmC levels are broadly decreased in breast cancer tissues and tightly linked with tumorigenesis. Therefore, detection of 5hmC may serve as a valuable biomarker for the diagnosis of breast cancer. Further more, Hsu [25] demonstrated the inhibition of the
invasiveness of breast cancer cells by TET1 in vivo and that down-regulation of TET1 expression in patients with breast cancer correlates with poor survival. The proof whether other proteins as well as TDG may serve as prognostic markers of breast cancer is lacking. In this present study, we further analyzed the association between the expression of mRNAs encoding TET1–3 and TDG with the prognosis of breast cancer patients.

Materials and Methods

Patients and samples

The present study included 162 patients who were diagnosed with early breast cancer (EBC) according to histopathological analyses conducted at Shanghai Cancer Center, Fudan University from April 2002 to November 2005. The early breast cancer patients in this cohort indicated those patients who can be treated with operation, namely early operable breast cancer. Breast cancer tissues were received immediately after surgery and stored at −80°C. The expression levels of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor-2 (HER-2) status were determined by the Department of Pathology of Shanghai Cancer Center, Fudan University according to the guidelines of the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) [27, 28]. Anthracycline is one of the chemotherapeutics and are commonly combined with platinum drugs in adjuvant therapy of breast cancer. We selected patients treated with commonly used anthracyclines to determine their prognoses as a function of expression levels of TET and TDG mRNAs.

RNA isolation and RT-PCR

Total RNA was extracted from breast cancer tissues using TRIZOL reagent (Invitrogen, Thermo Fisher Scientific Inc. Waltham, MA USA) and complementary DNA was synthesized using RT PCR kit (TOYOBO CO., LTD. Osaka, Japan) according to the manufacturer’s instructions.

Quantitative real-time PCR

PCR amplification was performed at 95°C for 60 s followed by 40 cycles at 95°C for 15 s, 60°C for 15 s, and 72°C for 45 s using an Applied Biosystems 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA) with 2.0 μl of cDNA and SYBR Green Real-time PCR Master Mix (Toyobo). Data were collected and analyzed using SDS2.4 Software (Applied Biosystems). Primer sequences are shown in Table 1.

Statistical analysis

Statistical analysis was performed using SPSS16.0 software. The levels of mRNAs encoding TETs and TDG were classified as high or low using a cutoff value equal to the median value of

Table 1. Primers used for real-time PCR analysis.

| Gene  | Forward primer (5’–3’)                | Reverse primer (5’–3’)               |
|-------|---------------------------------------|--------------------------------------|
| TET1  | CAGAACCTAAACCACCGTG                   | TGCTCGTGAGGCGCATTTGAA                |
| TET2  | GATAAGCAACCATGTTGAGGG                 | TGGAGCTTTTGTGACCAGAGGT               |
| TET3  | TCGGCCCACTCTAGAATGAG                  | AGGCCGTTGAAACTGACGT                  |
| TDG   | TGAAGCTCTATATGAGCGGT                 | TCCACTGTGGTGTGTGTGTGTC               |
| GAPDH | GCCTCAAGATCATCAGCAATGCCT             | TGGTGTCATGAGCTCCTTCAGCAT             |

doi:10.1371/journal.pone.0133896.t001
all patients’ samples. DFS and OS were calculated using the Kaplan–Meier method, and the log-rank test was used to determine the significance of differences between OS or DFS rates and the expression levels of mRNAs encoding TETs and TDG. \( P < 0.05 \) was considered statistically significant. Multivariate analysis was performed using the Cox regression model.

Ethical statement

The protocol for the use of human tissues was reviewed and approved by the Medical Ethics Committee of Cancer Hospital, Fudan University (Shanghai, China). Prior to the study, all patients gave their written informed consent to allow us to use leftover tissue samples for scientific research.

Results

Clinicopathological characteristics of patients

The median age of the 162 patients was 52 years (range, 33–84 years), and ages were distributed as follows: \( n = 130 \) (80.2%) >45 years; \( n = 32 \) (19.8%) <45 years. Ninety-three (57.4%) patients were postmenopausal and 69 (42.6%) were premenopausal. The sizes of tumors were as follows: \( n = 114 \) (70.4%) >2 cm and 48 (29.6%) <2 cm. Lymph node metastasis was detected in 71 (43.8%) patients. Disease stages (TNM) were as follows: \( n = 29 \) (17.9%), stage I; \( n = 102 \) (63.0%), stage II; and \( n = 31 \) (19.1%), stage III. Detection of ER, PR, and HER-2 expression was as follows: \( n = 69 \) (42.6%), \( n = 66 \) (40.7%), and \( n = 36 \) (22.2%) (Table 2).

Analysis of expression levels of TET1 mRNA and OS

The DFS and OS of all patients were 0.521 and 0.745 (Fig 1A), respectively. When patients were stratified according to high or low levels of TET1 expression, DFS was 0.580 or 0.448, respectively (\( P = 0.122 \)), and OS was 0.836 or 0.669, respectively (\( P = 0.022 \)) (Fig 1B). Prognosis was better for patients with high levels of TET2, TET3, and TDG mRNAs, although the differences were not statistically significant (\( P = 0.060 \)–0.122). Further, there was no significant correlation between the expression of any of the mRNAs with clinicopathological parameters such as TNM stage, ER, PR, and HER-2 status.

Evaluation of TNM stage as an independent prognostic factor for all patients

Multivariate analysis of DFS and OS indicated that TNM stage correlated with patients’ DFS (HR = 2.135, 95% CI: 1.070–4.263, \( P = 0.032 \)) and OS (HR = 1.761, 95% CI: 1.124–2.761, \( P = 0.014 \)) (Table 3), indicating that TNM stage was an independent factor for patients’ prognoses.

Comparison of TET3 and TDG mRNA levels with OS of patients treated with anthracyclines

After surgery, 114 (70%) patients received a chemotherapy regimen that included anthracyclines. Kaplan–Meier analysis indicated that higher levels of TET3 (\( P = 0.026 \)) and TDG (\( P = 0.030 \)) mRNAs associated with better DFS, but the association between TET3 (\( P = 0.171 \)) and TDG (\( P = 0.131 \)) mRNA levels and OS was not statistically significant. DFS and OS did not correlate significantly with TET1 or TET2 mRNA levels (\( P = 0.056 \)–0.109) (Fig 2).
Evaluation of TET3 and TDG mRNA levels as independent prognostic factors for patients treated with anthracyclines

Multivariate analysis revealed that high levels of TET3 (HR = 1.944, 95% CI: 1.029–3.672, \( P = 0.040 \)) and TDG (HR = 2.178, 95% CI: 1.140–4.163, \( P = 0.018 \)) mRNAs were independent indicators of favorable DFS (Table 4).

Discussion

Aberrant methylation of tumor suppressor genes is a hallmark of cancer pathogenesis and is caused by the dysregulation of DNA methylation and demethylation. TET family and TDG proteins represent key factors in the active DNA demethylation pathway. Moreover, a loss-of-function mutation in the TET2 gene is associated with hematological malignancies [18], and mutations in the three TET genes are related to solid tumors [22]. Hsu [25] reported an association between decreased 5hmC levels and TET expression in cancers. However, further investigations of the value of TET and TDG expression levels require further investigation.

In the present study, we analyzed patients’ clinicopathological characteristics and the levels of mRNAs encoding TET1–3 and TDG proteins that were present in tumor tissue. We found that TET1 expression closely correlated with OS. Hsu [25] reported that TET1 mRNA

**Table 2. Clinicopathological characteristics of patients.**

| Number of patients | 162 |
|--------------------|-----|
| Median age at diagnosis ± SD | 52 ± 10.4 |
| Age distribution (years) | | |
| <45 | 32 | 19.8% |
| ≥45 | 130 | 80.2% |
| Menopausal status | | |
| Premenopausal | 69 | 42.6% |
| Postmenopausal | 93 | 57.4% |
| Tumor size (cm) | | |
| ≤2 | 48 | 29.6% |
| >2 | 114 | 70.4% |
| Lymph node status | | |
| Negative | 91 | 56.2% |
| Positive | 71 | 43.8% |
| TNM stage | | |
| I | 29 | 17.9% |
| II | 102 | 63.0% |
| III | 31 | 19.1% |
| ER status | | |
| Negative | 93 | 57.4% |
| Positive | 69 | 42.6% |
| PR status | | |
| Negative | 96 | 59.3% |
| Positive | 66 | 40.7% |
| HER-2 status | | |
| Negative | 108 | 66.7% |
| Positive | 36 | 22.2% |
| NA | 18 | 11.1% |

doi:10.1371/journal.pone.0133896.t002
TET1, TET2, TET3 and TDG mRNAs and Breast Cancer
expression correlates inversely with the survival of patients with breast cancer patient and that down-regulation of TET expression correlates positively correlated with larger tumor size and advanced stage. We show here that OS was longer for patients with EBC with high levels of TET1 mRNA, which is consistent with Hsu's data. There was a similar trend for TET2, 3 and TDG expression, although the differences were not statistically significant. This may be explained by insufficient number of samples. Therefore, we hypothesized that expression level of TET2, 3 and TDG mRNAs may be associated with patients' prognosis. However, Cox regression analysis did not indicate TET1, 2, 3 and TDG mRNAs were independent predictors of breast cancer. Consistent with the results of other studies [29], we show here that TNM stage predicts prognosis of patients with EBC.

Anthracyclines are one of the most important and commonly used drugs for treating patients with breast cancer. We choose different chemotherapy regimens according to pathological types of breast tumors. Moreover, sensitivity to chemotherapy differs according to the different subtypes. Therefore, we asked whether the expression levels of the four mRNAs studied here were associated with patients' responses to chemotherapy and found that higher levels of TET3 and TDG mRNAs were associated with improved survival of patients treated with anthracyclines after surgery and served as independent prognostic factors. These findings indicate that patients who express high levels of TET3 and TDG mRNAs may benefit from further chemotherapy and that treatment with regimens including anthracyclines might be a good choice. However, the reliability and reproducibility of our findings require further study.

The results of our study are slightly limited by the proportion of patients in the cohort. Proportion of ER- or PR- patients were higher than that in general breast cancer patients. This might because these patients were diagnosed and treated in a certain time interval in Fudan University Shanghai Cancer Center, during which proportion of ER-/PR- patients were relatively high among all patients.

In summary, our study demonstrates that patients with breast cancer with high levels of TET1 mRNA had better OS than those with low expression of TET1 and that TNM stage was a prognostic factor. Further, the levels of TET3 and TDG mRNAs may serve to predict patients responses to anthracyclines and that the DFS of patients with high levels of TET3 and TDG mRNAs may be improved by treatment with anthracyclines.

Table 3. Multivariate analysis of DFS and OS in patients with EBC.

|       | DFS (95% CI) | P value | OS (95% CI) | P value |
|-------|-------------|---------|-------------|---------|
| Age (years) | 0.973 (0.504–1.878) | 0.935 | 1.712 (0.487–6.020) | 0.402 |
| TNM | 1.761 (1.124–2.761) | 0.014 | 2.135 (1.070–4.263) | 0.032 |
| ER | 0.730 (0.414–1.285) | 0.275 | 0.507 (0.198–1.302) | 0.158 |
| PR | 0.969 (0.550–1.707) | 0.912 | 1.277 (0.507–3.214) | 0.604 |
| HER-2 | 1.335 (0.924–1.929) | 0.124 | 0.642 (0.279–1.481) | 0.299 |
| TET1 | 0.757 (0.235–2.443) | 0.641 | 0.195 (0.031–1.246) | 0.084 |
| TET2 | 1.095 (0.325–3.690) | 0.884 | 2.597 (0.352–19.172) | 0.349 |
| TET3 | 0.856 (0.361–2.027) | 0.724 | 0.960 (0.219–4.216) | 0.957 |
| TDG | 0.786 (0.415–1.489) | 0.461 | 0.651 (0.223–1.90) | 0.432 |

Table 3. Multivariate analysis of DFS and OS in patients with EBC.
Fig 2. Kaplan–Meier analysis of DFS and OS as a function of TET3 and TDG expression. The levels of TET3 and TDG mRNAs correlated inversely with DFS in patients treated with anthracyclines. Higher levels of TET3 and TDG mRNAs correlated with better DFS (P = 0.026 and 0.030, respectively).

doi:10.1371/journal.pone.0133896.g002

Table 4. Multivariate analysis of DFS and OS in patients treated with anthracyclines.

|          | DFS                       |       | OS                        |       |
|----------|---------------------------|-------|---------------------------|-------|
|          | HR (95% CI)               | P value | HR (95% CI)               | P value |
| TET1     | 1.653 (0.880–3.108)       | 0.118 | 2.682 (0.850–8.460)       | 0.092  |
| TET2     | 1.817 (0.964–3.422)       | 0.065 | 2.249 (0.717–7.058)       | 0.165  |
| TET3     | 1.944 (1.029–3.672)       | 0.040 | 1.902 (0.617–5.867)       | 0.263  |
| TDG      | 2.178 (1.140–4.163)       | 0.018 | 1.902 (0.639–5.665)       | 0.248  |

doi:10.1371/journal.pone.0133896.t004
Acknowledgments

We thank all the subjects of this study for their participation. We greatly appreciate Jin Shen at Central Laboratory of Cancer Hospital, Fudan University for her excellent works in clinical specimen collection.

Author Contributions

Conceived and designed the experiments: LY SJY. Performed the experiments: LY SJY. Analyzed the data: LY. Contributed reagents/materials/analysis tools: QH YY ZMS. Wrote the paper: LY SJY. Obtained permission for patients’ tissue samples: ZMS.

References

1. Justo N, Wilking N, Jonsson B, Luciani S, Cazap E. A review of breast cancer care and outcomes in Latin America. The oncologist. 2013; 18(3):248–56. doi: 10.1634/theoncologist.2012-0373 PMID: 23442305; PubMed Central PMCID: PMC3607519.

2. Hassan MS, Ansari J, Spooner D, Hussain SA. Chemotherapy for breast cancer (Review). Oncology reports. 2010; 24(5):1121–31. PMID: 20878101.

3. Fan L, Strasser-Weippol K, Li J, St Louis J, Finkelstein DM, Yu K, et al. Breast cancer in China. The Lancet Oncology. 2014; 15(7):e279–89. doi: 10.1016/S1470-2045(13)70567-9 PMID: 24872111.

4. Hong W, Dong E. The past, present and future of breast cancer research in China. Cancer letters. 2014; 351(1):1–5. doi: 10.1016/j.canlet.2014.04.007 PMID: 24735750.

5. Hargreaves DC, Crabtree GR. ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. Cell research. 2011; 21(3):396–420. doi: 10.1038/cr.2011.32 PMID: 21358755; PubMed Central PMCID: PMC3110148.

6. Smith ZD, Chan MM, Humm KC, Karnik R, Melkhoubad S, Regev A, et al. DNA methylation dynamics of the human preimplantation embryo. Nature. 2014; 511(7511):61–5. doi: 10.1038/nature13581 PMID: 25079558; PubMed Central PMCID: PMC4178976.

7. Thiagarajan RD, Morey R, Laurent LC. The epigenome in pluripotency and differentiation. Epigenomics. 2014; 6(1):121–37. doi: 10.2217/epi.13.80 PMID: 24579950.

8. Brunet A, Berger SL. Epigenetics of aging and aging-related disease. The journals of gerontology Series A, Biological sciences and medical sciences. 2014; 69 Suppl 1:S17–20. doi: 10.1093/gerona/glu042 PMID: 24933581; PubMed Central PMCID: PMC4022130.

9. Robertson KD. DNA methylation and human disease. Nature reviews Genetics. 2005; 6(8):597–610. doi: 10.1038/nrg1655 PMID: 16136652.

10. Gopalakrishnan S, Van Emburgh BO, Robertson KD. DNA methylation in development and human disease. Mutation research. 2008; 647(1–2):30–8. doi: 10.1016/j.mrfmmm.2008.08.006 PMID: 18778722; PubMed Central PMCID: PMC2647981.

11. Wu Q, Yang Z, Xia L, Nie Y, Wu K, Shi Y, et al. Methylation of miR-129-5p CpG island modulates multidrug resistance in gastric cancer by targeting ABC transporters. OncoTargets and Therapy. 2014; 5(22):11552–63. PMID: 25344911; PubMed Central PMCID: PMC4294356.

12. Takeshima H, Wakabayashi M, Hattori N, Yamashita S, Ushijima T. Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy. Carcinogenesis. 2014. doi: 10.1093/carcin/bgu238 PMID: 25477340.

13. Milstein M, Mooser CK, Hu H, Fejzo M, Slamon D, Goodglick L, et al. RIN1 is a breast tumor suppressor gene. Cancer research. 2007; 67(24):11510–6. doi: 10.1158/0008-5472.CAN-07-1147 PMID: 18089779; PubMed Central PMCID: PMC2950063.

14. Kohli RM, Zhang Y. TET enzymes, TDG and the dynamics of DNA demethylation. Nature. 2013; 502(7472):472–9. doi: 10.1038/nature12750 PMID: 24153300; PubMed Central PMCID: PMC4046508.

15. Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009; 324(5929):930–5. doi: 10.1126/science.1170116 PMID: 19372391; PubMed Central PMCID: PMC2715015.

16. He YF, Li BZ, Li Z, Liu P, Wang Y, Tang Q, et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science. 2011; 333(6047):1303–7. doi: 10.1126/science.1210944 PMID: 21817016; PubMed Central PMCID: PMC3462231.
17. Wu YC, Ling ZQ. The role of TET family proteins and 5-hydroxymethylcytosine in human tumors. Histology and histopathology. 2014; 29(8):911–7. PMID: 24585390.
18. Chung YR, Schatoff E, Abdel-Wahab O. Epigenetic alterations in hematopoietic malignancies. International journal of hematology. 2012; 96(4):413–27. doi: 10.1007/s12185-012-1181-z PMID: 23015417.
19. Takahashi S. Epigenetic aberrations in myeloid malignancies (Review). International journal of molecular medicine. 2013; 32(3):532–8. doi: 10.3892/ijmm.2013.1417 PMID: 23760684.
20. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nature genetics. 2013; 45(8):860–7. doi: 10.1038/ng.2699 PMID: 23797736.
21. Nickerson ML, Im KM, Misner KJ, Tan W, Lou H, Gold B, et al. Somatic alterations contributing to metastasis of a castration-resistant prostate cancer. Human mutation. 2013; 34(9):1231–41. doi: 10.1002/humu.22346; PubMed Central PMCID: PMC3745530.
22. Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, et al. Recurrent R-spondin fusions in colon cancer. Nature. 2012; 488(7413):660–4. doi: 10.1038/nature11282 PMID: 22895193; PubMed Central PMCID: PMC3690621.
23. Lian CG, Xu Y, Ceol C, Wu F, Larson A, Dresser K, et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell. 2012; 150(6):1135–46. doi: 10.1016/j.cell.2012.07.033 PMID: 22980977; PubMed Central PMCID: PMC3770275.
24. Gambichler T, Sand M, Skrygan M. Loss of 5-hydroxymethylcytosine and ten-eleven translocation 2 protein expression in malignant melanoma. Melanoma research. 2013; 23(3):218–20. doi: 10.1097/CMR.0b013e32835f9bd4 PMID: 23458759.
25. Hsu CH, Peng KL, Kang ML, Chen YR, Yang YC, Tsai CH, et al. TET1 suppresses cancer invasion by activating the tissue inhibitors of metalloproteinases. Cell reports. 2012; 2(3):568–79. doi: 10.1016/j.celrep.2012.08.030 PMID: 22999938.
26. Yang H, Liu Y, Bai F, Zhang JY, Ma SH, Liu J, et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene. 2013; 32(5):663–9. doi: 10.1038/onc.2012.67 PMID: 22391558; PubMed Central PMCID: PMC3897214.
27. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28(16):2784–95. doi: 10.1200/JCO.2009.25.6529 PMID: 20404251; PubMed Central PMCID: PMC2881855.
28. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31(31):3997–4013. doi: 10.1200/JCO.2013.50.9984 PMID: 24101045.
29. Chen L, Romond E, Chokshi S, Saeed H, Hodskins J, Stevens M, et al. A prognostic model of early breast cancer relapse after standard adjuvant therapy and comparison with metastatic disease on initial presentation. Breast cancer research and treatment. 2012; 136(2):565–72. doi: 10.1007/s10549-012-2265-4 PMID: 23053651.